Drug intelligence / Profile preview

CIM102

Development stage: Unknown
Lead developer: CiMaas
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CIM102 is a CiMaas investigational combination immunotherapy for metastatic breast cancer that combines donor-derived NK-Xpand natural killer cells with the anti-HER2 monoclonal antibody trastuzumab. Trastuzumab directs therapy toward HER2-expressing tumor cells, while the NK cells are intended to enhance antibody-dependent cellular cytotoxicity through Fc receptor engagement. ([cimaas.com](https://cimaas.com/pipeline/))

Targets

FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on CIM102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIM102.

Explore the full profile